Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) Enterprise Value (2016 - 2026)

Mimedx's Enterprise Value history spans 17 years, with the latest figure at -$159.8 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 50.12% to -$159.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$159.8 million, a 50.12% decrease, with the full-year FY2025 number at -$166.1 million, down 59.1% from a year prior.
  • Enterprise Value hit -$159.8 million in Q1 2026 for Mimedx, up from -$166.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for MDXG hit a ceiling of -$48.5 million in Q1 2024 and a floor of -$166.1 million in Q4 2025.
  • Historically, Enterprise Value has averaged -$94.0 million across 5 years, with a median of -$78.8 million in 2022.
  • Biggest five-year swings in Enterprise Value: increased 24.27% in 2022 and later tumbled 119.5% in 2025.
  • Tracing MDXG's Enterprise Value over 5 years: stood at -$66.0 million in 2022, then decreased by 24.34% to -$82.0 million in 2023, then fell by 27.34% to -$104.4 million in 2024, then crashed by 59.1% to -$166.1 million in 2025, then rose by 3.82% to -$159.8 million in 2026.
  • Business Quant data shows Enterprise Value for MDXG at -$159.8 million in Q1 2026, -$166.1 million in Q4 2025, and -$142.1 million in Q3 2025.